Seattle-based cell- and immune-analysis company Ozette has launched its Assay-to-Insights product, which combines three company-developed technologies: Ozette Laboratory, Ozette Endpoints, and Ozette Discovery. The Ozette Laboratory, under GCLP guidelines, generates full-spectrum cytometry data using the company's 48-color pan-immuno-phenotype panel. Ozette Endpoints provides rapid computational monitoring of pre-defined biomarker endpoints, while Ozette Discovery enables unbiased discovery and annotation of this single-cell cytometry data. The Ozette platform is cloud-based, allowing research teams to interact with and explore cytometry data in a central dashboard. The company said its combined product provides clinically relevant insights from single-cell cytometry data and supports the entire development cycle of a therapy, from preclinical research through FDA approval.